Repository hosted by TU Delft Library

Home · Contact · About · Disclaimer ·
 

D-Tagatose increases butyrate production by the colonic microbiota in healthy men and women

Publication files not online:

Author: Venema, K. · Vermunt, S.H.F. · Brink, E.J.
Type:article
Date:2005
Institution: TNO Kwaliteit van Leven
Source:Microbial Ecology in Health and Disease, 1, 17, 47-57
Identifier: 238422
doi: doi:10.1080/08910600510035093
Keywords: Health · Biomedical Research · Butyrate · Colon · D-tagatose · Gastrointestinal health · Healthy subjects · Microbiota · butyric acid · fructose oligosaccharide · lipid · placebo · prebiotic agent · short chain fatty acid · sucrose · tagatose · article · clinical trial · colon flora · controlled clinical trial · controlled study · crossover procedure · defecation · double blind procedure · female · gastrointestinal symptom · human · human experiment · in vitro study · in vivo study · incubation time · intestine absorption · Lactobacillus · male · normal human · parameter · priority journal · questionnaire · randomized controlled trial · safety · stomach absorption · Acacia acuminata · Microbiota · Rubus glaucus

Abstract

D-Tagatose is partly absorbed in the stomach and small intestine. Most of it is fermented by the large intestinal microbiota. The effect of D-tagatose on the composition of the microbiota and production of short chain fatty acids (SCFAs) was studied in vivo and in vitro. Gastrointestinal (GI) complaints were also studied. The in vivo study was performed according to a randomized, placebo-controlled, double-blind, five-way cross-over design in healthy subjects (12 men and 18 women). All subjects consumed 30 g raspberry jam containing 7.5 or 12.5 g D-tagatose, 7.8 g fructo-oligosaccharides (positive reference), 7.6 g D-tagatose plus 7.5 g fructo-oligosaccharides, or 15.1 g sucrose (negative reference) at breakfast for 2 weeks in different orders. At the end of each treatment period lipids and safety parameters in blood and GI complaints were evaluated by questionnaires, and faecal microbiota and SCFAs were measured. Furthermore, test-tube incubations of faecal slurries with D-tagatose, fructo-oligosaccharides and sucrose were performed. An in vitro model simulating the large intestine was used to assess the mechanistic effect of D-tagatose on microbiota composition and SCFA production. The high-tagatose treatment resulted in increased numbers of faecal lactobacilli in men, but not in women. Also in vitro, lactobacilli increased. Both the test-tube incubations of fresh faeces from the in vivo study with D-tagatose and the study in the in vitro model showed increased butyrate production after all treatments with D-tagatose. High-tagatose, but not low-tagatose, resulted in a slightly increased defecation frequency and stools of thinner consistency. Only a few GI complaints were reported. The data indicate that daily consumption of 7.5 or 12.5 g D-tagatose may lead to increased production of butyrate and to an increase of lactobacilli, without serious GI complaints. In view of the health-promoting effects of butyrate and lactobacilli, D-tagatose may be considered a prebiotic substrate. © 2005 Taylor & Francis Group Ltd.